A Study of the PK, Safety and Antiviral Activity of A-831 in HCV Carriers
Status:
Terminated
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
The purposes of this study are:
- to determine the safety and tolerability of multiple doses of A-831 at various doses
- to determine how multiple doses of A-831 are distributed through the bloodstream
- to determine if A-831 reduces the amount of Hepatitis C virus in the blood
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Arrow Therapeutics
Collaborators:
David Mutimer, Birmingham DDS, Dundee Ed Gane, ACS New Zealand